Physician profile
Lorren C Mott
NPI 1306897186
$6,134.91
in general payments reported to CMS, 2019-2025
39 companies · $720 in 2025
The $720 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $637 · 2021: $897 · 2022: $1,192 · 2023: $985 · 2024: $728 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,143.09 | 2019-2025 | |
| Acutus Medical, INC. | $505.00 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $500.78 | 2019-2024 | Camzyos, Eliquis |
| Heartflow, INC. | $455.19 | 2020-2022 | |
| Pfizer INC. | $415.57 | 2019-2024 | |
| Amgen INC. | $381.71 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $283.60 | 2021-2024 | Verquvo |
| Amarin Pharma, INC. | $235.09 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.85 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $198.88 | 2019-2024 | Xarelto |
| Abbott Laboratories | $168.56 | 2019-2024 | Cardiomems, Ensite |
| Astrazeneca Pharmaceuticals LP | $155.19 | 2019-2024 | Farxiga, Andexxa |
| Penumbra, INC. | $149.11 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $122.79 | 2020-2025 | Lifevest |
| Inspire Medical Systems, INC. | $121.31 | 2024-2025 | Inspire |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $109.35 | 2019-2024 | Evkeeza, Praluent |
| Novo Nordisk INC | $93.12 | 2021-2025 | Wegovy, Ozempic |
| Boston Scientific Corporation | $88.46 | 2019-2025 | Apollo Esg System |
| Sanofi-Aventis U.S. LLC | $75.71 | 2019-2020 | |
| Cleerly, INC. | $75.24 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Actelion Pharmaceuticals US, INC. | $74.93 | 2019-2021 | |
| Inari Medical, INC. | $59.45 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Scpharmaceuticals INC. | $56.30 | 2023-2025 | |
| Ge Healthcare | $55.50 | 2025 | |
| Lundbeck LLC | $39.57 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $37.39 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.56 | 2025 | |
| Medtronic, INC. | $31.61 | 2025 | Symplicity G3, Selectsite |
| Ebr Systems, INC. | $31.23 | 2025 | |
| United Therapeutics Corporation | $28.50 | 2019 | |
| Recor Medical INC | $27.69 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Kiniksa Pharmaceuticals International, Plc | $24.61 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $23.87 | 2024 | Givlaari |
| Vital Connect, INC | $18.98 | 2025 | Vitalpatch Rtm |
| Kowa Pharmaceuticals America, INC. | $18.41 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.02 | 2024 | |
| Cvrx, INC. | $16.02 | 2024 | Barostim Neo System |
| Atricure, INC. | $15.41 | 2023 | |
| Esperion Therapeutics, INC. | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorren Mott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.